Shots:
- Lupin has entered into a licensing agreement with Sandoz to market & commercialize Lupin’s ranibizumab biosimilar in multiple regions
- As per the deal, Sandoz will commercialize the product in the EU (excl. Germany), Switzerland, Norway, Australia, Hong Kong, Vietnam, & Malaysia, while holding exclusive rights in most markets & semi-exclusive rights in France, Australia, Vietnam, & Malaysia, with Lupin handling manufacturing & regulatory filings
- Sandoz will acquire exclusive Canadian commercialization rights for Lupin’s biosimilar ranibizumab, under another agreement between the companies, with Lupin responsible for manufacturing & regulatory filings
Ref: Lupin| Image: Lupin and Sandoz | Press Release
Related News:- Sandoz Reports EC’s Approval of Wyost and Jubbonti (Biosimilars, Xgeva and Prolia)
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
